Close
Nordic 9Nordic 9

Mission BioCapital (investor - Venture Capital)

United States missionbiocapital.com
See something wrong or missing? Let us know
Offices:Cambridge

Mission BioCapital is a life science venture capital firm that invests in early-stage companies.

Average round investment:36.31M USD
Average number per year:1.0
Distribution: 2025 (1)2024 (1)2022 (1)
Portfolio companies: France Enodia TherapeuticsSwitzerland ImmunOs Therapeutics
Mostly invests in: Switzerland Switzerland (2) Biotech (3)

3 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Mission BioCapital mostly invests with:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Mission BioCapital

Name Criteria
United States Acorn Bioventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States KB Partners
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland, France
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden Recipharm Venture Fund
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
France Roquette Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Supermoon Capitals
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
China Zhejiang NHU
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Mayo Clinic
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
France BOLD - Business Opportunities for L'Oréal Development
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland, France
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
France Didier Rousseau
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
France Inserm Transfert Initiative
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Top